Skip to content

Cognitive dysfunction and developmental risks for severe psychopathology: insights from sex chromosomal disorders

Cognitive dysfunction and developmental risks for severe psychopathology: insights from sex chromosomal disorders - Neurodevelopmental risks in sex chromosomal disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32524
Enrollment
200
Registered
2009-04-02
Start date
2009-04-20
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sex chromosomal aneuploidy sex chromosomal disorder

Interventions

None listed

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: General inclusion criteria include age between 4 and 12 (for the fMRI study: age between 9 and 12), voluntary participation, Dutch speaking and signed informed consent from parents. The specific inclusion criteria for the four groups are as following:;Klinefelter syndrome: diagnosed with (non-mosaic) Klinefelter syndrome based on the presence of a 47,XXY chromosomal pattern as determined by karyotyping. Turner syndrome: diagnosed with (non-mosaic) Turner syndrome based on the presence of a 46,XO chromosomal pattern as determined by karyotyping. Autism spectrum condition: an autism spectrum diagnosis according to DSM-IV or ICD-10 criteria Non-clinical controls: n/a

Exclusion criteria

Exclusion criteria: Clinical groups: - history of closed-head injury or neurological illness - contraindications for MRI (part 2 study) - premature birth;Non-clinical groups: - use of psychotropic medication - history of psychiatric illness, closed-head injury, neurological illness or endocrinological dysfunction - contraindications for fMRI - premature birth

Design outcomes

Primary

MeasureTime frame
cognitive dysfunctions in relation to social behavioural difficulties, differences between the groups in BOLD (blood oxygen level dependent) response during cognitive tasks and FA (Fractional Anisotropy) as measured with MRI, levels of testosterone as measured in saliva samples.

Secondary

MeasureTime frame
number of adverse events

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)